Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis

Approximately 98  % of males with cystic fibrosis (MwCF) are infertile, primarily due to congenital bilateral absence of the vas deferens (CBAVD) [1,2]. Additionally, studies performed prior to widespread use of highly effective CF transmembrane conductance regulator (CFTR) modulator therapies (HEMT) have found tha t hypogonadism or testosterone deficiency occurs among as many as 28–45 % of MwCF. Untreated hypogonadism can lead to pubertal delay, decreased muscle mass and bone density, fatigue, decreased libido, sexual dysfunction, and depression [3,4].

Source: Journal of Cystic Fibrosis - November 10, 2023 Category: Respiratory Medicine Authors: Traci M. Kazmerski, Olivia M. Stransky, Danielle R. Lavage, Kara S. Hughan, Raksha Jain, Sigrid L. Ladores, Michael S. Stalvey, Vin Tangpricha, Jennifer L. Taylor-Cousar, Natalie E. West, Gregory S. Sawicki Tags: Original Article Source Type: research